SEC Filing » Gritstone bio

View:

Download DOC

Download PDF

Download XLS

SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c)

AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. 1)

Gritstone Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

39868T105

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☐

Rule 13d-1(c)

☒

Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Venture Capital V, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 2,723,031 shares of Common Stock (2)
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 2,723,031 shares of Common Stock (2)
		8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,723,031 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 5.7% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)

This Schedule 13G is filed by Versant Venture Capital V, L.P. (“VVC V”), Versant Affiliates Fund V, L.P. (“VAF V”), Versant Ophthalmic Affiliates Fund I, L.P. (“VOA”), Versant Venture Capital V (Canada) LP (“VVC CAN”) and Versant Vantage I, L.P. (“VV I”). Versant Ventures V, LLC (“VV V”) is the sole general partner of VVC V, VAF V and VOA. Samuel D. Colella (“Colella”), Jerel C. Davis (“Davis”), William J. Link (“Link”), Bradley Bolzon, Ph.D (“Bolzon”), Kirk G. Nielsen (“Nielsen”), Thomas Woiwode (“Woiwode”) and Robin L. Praeger (“Praeger”) are managing directors of VV V. Versant Ventures V GP-GP (Canada), Inc. (“VV V CAN GP”) is the sole general partner of Versant Ventures V (Canada), L.P. (“VV V CAN”) and VV V CAN is the sole general partner of VVC CAN. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are directors of VV V CAN GP. Versant Vantage I GP-GP, LLC (“VV I GP-GP”) is the sole general partner of Versant Vantage I GP, L.P. (“VV I GP”, and, together with VVC V, VV V, VAF V, VOA, VVC CAN, VV V CAN, VV V CAN GP, VV I and VV I GP-GP, the “Reporting Persons”). VV I GP is the sole general partner of VV I. Bolzon, Davis, Clare Ozawa (“Ozawa”), Woiwode and Praeger are managing directors of VV I GP-GP. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

These shares are held by VVC V. VV V is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VVC V.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Affiliates Fund V, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 81,908 shares of Common Stock (2)
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 81,908 shares of Common Stock (2)
		8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 81,908 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 0.2% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

These shares are held by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VAF V.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Ophthalmic Affiliates Fund I, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 90,756 shares of Common Stock (2)
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 90,756 shares of Common Stock (2)
		8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 90,756 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 0.2% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

These shares are held by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VOA.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Ventures V, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,895,695 shares of Common Stock (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,895,695 shares of Common Stock (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,895,695 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 6.1% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

Includes (i) 2,723,031 shares held by VVC V, (ii) 81,908 shares held by VAF and (iii) 90,756 shares held by VOA. VV V is the sole general partner of VVC V, VAF and VOA and may be deemed to have voting and dispositive power over the securities held by VVC V, VAF and VOA. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V and share voting and dispositive power over the shares held by VVC V, VAF and VOA.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Venture Capital V (Canada) LP
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Ontario, Canada
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 207,234 shares of Common Stock (2)
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 207,234 shares of Common Stock (2)
		8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 207,234 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 0.4% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)	These shares are held by VVC CAN. VV V CAN GP is the sole general partner of VV V CAN and VV V CAN is the sole general partner of VVC CAN. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Ventures V GP-GP (Canada), Inc.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 207,234 shares of Common Stock (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 207,234 shares of Common Stock (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 207,234 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 0.4% (3)
12.	Type of Reporting Person (See Instructions) CO

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)	These shares are held by VVC CAN. VV V CAN GP is the sole general partner of VV V CAN and VV V CAN is the sole general partner of VVC CAN. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Ventures V (Canada), L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 207,234 shares of Common Stock (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 207,234 shares of Common Stock (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 207,234 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 0.4% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)	These shares are held by VVC CAN. VV V CAN GP is the sole general partner of VV V CAN and VV V CAN is the sole general partner of VVC CAN. Colella, Davis, Link, Bolzon, Praeger, Nielsen and Woiwode are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Vantage I, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 1,347,709 shares of Common Stock (2)
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 1,347,709 shares of Common Stock (2)
		8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,347,709 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 2.8% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)	These shares are held by VV I. VV I GP-GP is the sole general partner of VV I GP and VV I GP is the sole general partner of VV I. Bolzon, Davis, Ozawa, Woiwode and Praeger are the managing directors of VV I GP-GP and share voting and dispositive power over the shares held by VV I.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Vantage I GP, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,347,709 shares of Common Stock (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,347,709 shares of Common Stock (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,347,709 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 2.8% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)	These shares are held by VV I. VV I GP-GP is the sole general partner of VV I GP and VV I GP is the sole general partner of VV I. Bolzon, Davis, Ozawa, Woiwode and Praeger are the managing directors of VV I GP-GP and share voting and dispositive power over the shares held by VV I.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.


CUSIP No. 39868T105		13G


1.	Name of Reporting Persons Versant Vantage I GP-GP, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒ (1)
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 1,347,709 shares of Common Stock (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 1,347,709 shares of Common Stock (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,347,709 shares of Common Stock (2)
10.	Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row 9 2.8% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)	These shares are held by VV I. VV I GP-GP is the sole general partner of VV I GP and VV I GP is the sole general partner of VV I. Bolzon, Davis, Ozawa, Woiwode and Praeger are the managing directors of VV I GP-GP and share voting and dispositive power over the shares held by VV I.

(3)	This calculation is based upon 47,552,693 shares of the Issuer’s Common Stock outstanding as of December 31, 2020, as reported by the Issuer to the Reporting Persons.

Introductory Note: This Amendment No. 1 (“Amendment”) amends and supplements the Schedule 13G originally filed by the Reporting Persons with the United States Securities and Exchange Commission (the “Commission”) on February 14, 2019 (the “Original Schedule 13G”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13G.


Item 1
	(a)	Name of Issuer: Gritstone Oncology, Inc.
		Address of Issuer’s Principal Executive Offices: 5959 Horton Street, Suite 300 Emeryville, California 94608
Item 2
	(a)	Name of Person(s) Filing: Versant Venture Capital V, L.P. (“VVC V”) Versant Affiliates Fund V, L.P. (“VAF V”) Versant Ophthalmic Affiliates Fund I, L.P. (“VOA”) Versant Ventures V, LLC (“VV V”) Versant Venture Capital V (Canada) LP (“VVC CAN”) Versant Ventures V GP-GP (Canada), Inc. (“VV V CAN GP”) Versant Ventures V (Canada), L.P. (“VV V CAN”) Versant Vantage I, L.P. (“VV I”) Versant Vantage I GP, L.P. (“VV I GP”) Versant Vantage I GP-GP, LLC (“VV I GP-GP”)
	(c)	Citizenship:

		Entities:	VVC V	—	Delaware

			VAF V	—	Delaware

			VV V	—	Delaware

			VOA	—	Delaware

			VVC CAN	—	Ontario, Canada

			VV V CAN GP	—	Delaware

			VV V CAN	—	Delaware

			VV I	—	Delaware

			VV I GP	—	Delaware

			VV I GP-GP	—	Delaware
	(d)	Title of Class of Securities: Common Stock
	(e)	CUSIP Number: 39868T105

Item 4

Ownership.

The following information with respect to the ownership of the Issuer’s Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020:

(a)

Amount beneficially owned:

See line 9 of each cover sheet.

(b)

Percent of class:

See line 11 of each cover sheet.

(c)

Number of shares as to which the person has:

Sole power to vote or to direct the vote: see line 5 of cover sheets.*

ii.

Shared power to vote or to direct the vote: see line 6 of cover sheets.*

iii.

Sole power to dispose or to direct the disposition of: see line 7 of cover sheets.*

iv.

Shared power to dispose or to direct the disposition of: see line 8 of cover sheets.*

*	Each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record and to the extent of its pecuniary interest therein.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


February 16, 2021

Versant Venture Capital V, L.P.

By: Versant Ventures V, LLC
Its: General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Affiliates Fund V, L.P.

By: Versant Ventures V, LLC
Its: General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Ophthalmic Affiliates Fund I, L.P.

By: Versant Ventures V, LLC
Its: General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Ventures V, LLC

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Venture Capital V (Canada) LP

By: Versant Ventures V (Canada), L.P.
Its: General Partner
By: Versant Ventures V GP-GP (Canada), Inc.
Its: General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Director

Versant Ventures V (Canada), L.P.

By: Versant Ventures V GP-GP (Canada), Inc.
Its: General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Director

Versant Ventures V GP-GP (Canada), Inc.

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Director

Versant Vantage I, L.P.

By: Versant Vantage I GP, L.P.
Its: General Partner
By: Versant Vantage I GP-GP, LLC
Its: General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Vantage I GP, L.P.

By: Versant Vantage I GP-GP, LLC
Its: General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Vantage I GP-GP, LLC

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

EX-99.1

Exhibit 1

Joint Filing Agreement

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Gritstone Oncology, Inc. is filed on behalf of each of us.


February __, 2021

Versant Venture Capital V, L.P.

By:		Versant Ventures V, LLC
Its:		General Partner
By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Affiliates Fund V, L.P.

By:		Versant Ventures V, LLC
Its:		General Partner
By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Ophthalmic Affiliates Fund I, L.P.

By:		Versant Ventures V, LLC
Its:		General Partner
By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Ventures V, LLC

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Venture Capital V (Canada) LP

By:		Versant Ventures V (Canada), L.P.
Its:		General Partner
By:		Versant Ventures V GP-GP (Canada), Inc.
Its:		General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Director

Versant Ventures V (Canada), L.P.

By:		Versant Ventures V GP-GP (Canada), Inc.
Its:		General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Director

Versant Ventures V GP-GP (Canada), Inc.

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Director

Versant Vantage I, L.P.

By:		Versant Vantage I GP, L.P.
Its:		General Partner
By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director

Versant Vantage I GP, L.P.

By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director



Versant Vantage I GP-GP, LLC

By:		/s/ Robin L. Praeger
		Robin L. Praeger, Managing Director